Shots: Ionis Pharmaceuticals will receive an upfront payment in ordinary shares $2.5M, $22.23/share representing 20% premium plus milestones payments and 20% royalties on net sales of QR-1123. ProQR to get WW license rights for Ionis’ IONIS-RHO-2.5 Candidate In 2019, ProQR plans onset of P-I/II trial for QR-1123 in autosomal dominant retinitis pigmentosa (adRP) with awaited […]Read More
